Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

Fabio P.S. Santos, Hagop M. Kantarjian, Nitin Jain, Taghi Manshouri, Deborah A. Thomas, Guillermo Garcia-Manero, Debra Kennedy, Zeev Estrov, Jorge Cortes, Srdan Verstovsek

Research output: Contribution to journalArticle

Abstract

Few treatment options exist for patients with myelofibrosis (MF), and their survival is significantly shortened. Activating mutation of the JAK2 tyrosine kinase (JAK2V617F) is found in approximately 50% of MF patients. CEP-701 is a tyrosine kinase inhibitor that inhibits JAK2 in in vitro and in vivo experiments. We conducted a phase 2 clinical study of CEP-701 in 22 JAK2V617F-positive MF patients (80 mg orally twice daily), and 6 (27%) responded by International Working Group criteria (clinical improvement in all cases): reduction in spleen size only (n = 3), transfusion independency (n = 2), and reduction in spleen size with improvement in cytopenias (n = 1). Median time to response was 3 months, and duration of response was more than or equal to 14 months. No improvement was seen in bone marrow fibrosis or JAK2 V617F allele burden. Phosphorylated STAT3 levels decreased from baseline in responders while on therapy. Eight patients (36%) experienced grade 3 or 4 toxicity, and 6 (27%) required dose reduction. Main side effects were myelosuppression (grade 3 or 4 anemia, 14%; and thrombocytopenia, 23%) and gastrointestinal disturbances (diarrhea, any grade, 72%; grade 3 or 4, 9%; nausea, grade 1 or 2 only, 50%; vomiting, grade 1 or 2 only, 27%). In conclusion, CEP-701 resulted in modest efficacy and mild but frequent gastrointestinal toxicity in MF patients. The study was registered at http://clinicaltrials.gov as NCT00494585.

Original languageEnglish (US)
Pages (from-to)1131-1136
Number of pages6
JournalBlood
Volume115
Issue number6
DOIs
StatePublished - Feb 11 2010
Externally publishedYes

Fingerprint

Essential Thrombocythemia
Polycythemia Vera
Primary Myelofibrosis
Protein-Tyrosine Kinases
Toxicity
Spleen
Bone
Thrombocytopenia
Nausea
Vomiting
Anemia
Diarrhea
Alleles
lestaurtinib
Experiments
Mutation
Survival
Therapeutics

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Santos, F. P. S., Kantarjian, H. M., Jain, N., Manshouri, T., Thomas, D. A., Garcia-Manero, G., ... Verstovsek, S. (2010). Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood, 115(6), 1131-1136. https://doi.org/10.1182/blood-2009-10-246363

Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. / Santos, Fabio P.S.; Kantarjian, Hagop M.; Jain, Nitin; Manshouri, Taghi; Thomas, Deborah A.; Garcia-Manero, Guillermo; Kennedy, Debra; Estrov, Zeev; Cortes, Jorge; Verstovsek, Srdan.

In: Blood, Vol. 115, No. 6, 11.02.2010, p. 1131-1136.

Research output: Contribution to journalArticle

Santos, FPS, Kantarjian, HM, Jain, N, Manshouri, T, Thomas, DA, Garcia-Manero, G, Kennedy, D, Estrov, Z, Cortes, J & Verstovsek, S 2010, 'Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis', Blood, vol. 115, no. 6, pp. 1131-1136. https://doi.org/10.1182/blood-2009-10-246363
Santos, Fabio P.S. ; Kantarjian, Hagop M. ; Jain, Nitin ; Manshouri, Taghi ; Thomas, Deborah A. ; Garcia-Manero, Guillermo ; Kennedy, Debra ; Estrov, Zeev ; Cortes, Jorge ; Verstovsek, Srdan. / Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. In: Blood. 2010 ; Vol. 115, No. 6. pp. 1131-1136.
@article{e3c856eb4e354d3cb55b51bba3eb6d10,
title = "Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis",
abstract = "Few treatment options exist for patients with myelofibrosis (MF), and their survival is significantly shortened. Activating mutation of the JAK2 tyrosine kinase (JAK2V617F) is found in approximately 50{\%} of MF patients. CEP-701 is a tyrosine kinase inhibitor that inhibits JAK2 in in vitro and in vivo experiments. We conducted a phase 2 clinical study of CEP-701 in 22 JAK2V617F-positive MF patients (80 mg orally twice daily), and 6 (27{\%}) responded by International Working Group criteria (clinical improvement in all cases): reduction in spleen size only (n = 3), transfusion independency (n = 2), and reduction in spleen size with improvement in cytopenias (n = 1). Median time to response was 3 months, and duration of response was more than or equal to 14 months. No improvement was seen in bone marrow fibrosis or JAK2 V617F allele burden. Phosphorylated STAT3 levels decreased from baseline in responders while on therapy. Eight patients (36{\%}) experienced grade 3 or 4 toxicity, and 6 (27{\%}) required dose reduction. Main side effects were myelosuppression (grade 3 or 4 anemia, 14{\%}; and thrombocytopenia, 23{\%}) and gastrointestinal disturbances (diarrhea, any grade, 72{\%}; grade 3 or 4, 9{\%}; nausea, grade 1 or 2 only, 50{\%}; vomiting, grade 1 or 2 only, 27{\%}). In conclusion, CEP-701 resulted in modest efficacy and mild but frequent gastrointestinal toxicity in MF patients. The study was registered at http://clinicaltrials.gov as NCT00494585.",
author = "Santos, {Fabio P.S.} and Kantarjian, {Hagop M.} and Nitin Jain and Taghi Manshouri and Thomas, {Deborah A.} and Guillermo Garcia-Manero and Debra Kennedy and Zeev Estrov and Jorge Cortes and Srdan Verstovsek",
year = "2010",
month = "2",
day = "11",
doi = "10.1182/blood-2009-10-246363",
language = "English (US)",
volume = "115",
pages = "1131--1136",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "6",

}

TY - JOUR

T1 - Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

AU - Santos, Fabio P.S.

AU - Kantarjian, Hagop M.

AU - Jain, Nitin

AU - Manshouri, Taghi

AU - Thomas, Deborah A.

AU - Garcia-Manero, Guillermo

AU - Kennedy, Debra

AU - Estrov, Zeev

AU - Cortes, Jorge

AU - Verstovsek, Srdan

PY - 2010/2/11

Y1 - 2010/2/11

N2 - Few treatment options exist for patients with myelofibrosis (MF), and their survival is significantly shortened. Activating mutation of the JAK2 tyrosine kinase (JAK2V617F) is found in approximately 50% of MF patients. CEP-701 is a tyrosine kinase inhibitor that inhibits JAK2 in in vitro and in vivo experiments. We conducted a phase 2 clinical study of CEP-701 in 22 JAK2V617F-positive MF patients (80 mg orally twice daily), and 6 (27%) responded by International Working Group criteria (clinical improvement in all cases): reduction in spleen size only (n = 3), transfusion independency (n = 2), and reduction in spleen size with improvement in cytopenias (n = 1). Median time to response was 3 months, and duration of response was more than or equal to 14 months. No improvement was seen in bone marrow fibrosis or JAK2 V617F allele burden. Phosphorylated STAT3 levels decreased from baseline in responders while on therapy. Eight patients (36%) experienced grade 3 or 4 toxicity, and 6 (27%) required dose reduction. Main side effects were myelosuppression (grade 3 or 4 anemia, 14%; and thrombocytopenia, 23%) and gastrointestinal disturbances (diarrhea, any grade, 72%; grade 3 or 4, 9%; nausea, grade 1 or 2 only, 50%; vomiting, grade 1 or 2 only, 27%). In conclusion, CEP-701 resulted in modest efficacy and mild but frequent gastrointestinal toxicity in MF patients. The study was registered at http://clinicaltrials.gov as NCT00494585.

AB - Few treatment options exist for patients with myelofibrosis (MF), and their survival is significantly shortened. Activating mutation of the JAK2 tyrosine kinase (JAK2V617F) is found in approximately 50% of MF patients. CEP-701 is a tyrosine kinase inhibitor that inhibits JAK2 in in vitro and in vivo experiments. We conducted a phase 2 clinical study of CEP-701 in 22 JAK2V617F-positive MF patients (80 mg orally twice daily), and 6 (27%) responded by International Working Group criteria (clinical improvement in all cases): reduction in spleen size only (n = 3), transfusion independency (n = 2), and reduction in spleen size with improvement in cytopenias (n = 1). Median time to response was 3 months, and duration of response was more than or equal to 14 months. No improvement was seen in bone marrow fibrosis or JAK2 V617F allele burden. Phosphorylated STAT3 levels decreased from baseline in responders while on therapy. Eight patients (36%) experienced grade 3 or 4 toxicity, and 6 (27%) required dose reduction. Main side effects were myelosuppression (grade 3 or 4 anemia, 14%; and thrombocytopenia, 23%) and gastrointestinal disturbances (diarrhea, any grade, 72%; grade 3 or 4, 9%; nausea, grade 1 or 2 only, 50%; vomiting, grade 1 or 2 only, 27%). In conclusion, CEP-701 resulted in modest efficacy and mild but frequent gastrointestinal toxicity in MF patients. The study was registered at http://clinicaltrials.gov as NCT00494585.

UR - http://www.scopus.com/inward/record.url?scp=77949535491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949535491&partnerID=8YFLogxK

U2 - 10.1182/blood-2009-10-246363

DO - 10.1182/blood-2009-10-246363

M3 - Article

C2 - 20008298

AN - SCOPUS:77949535491

VL - 115

SP - 1131

EP - 1136

JO - Blood

JF - Blood

SN - 0006-4971

IS - 6

ER -